Cost-utility analysis of a ‘vonoprazan-first’ strategy versus ‘esomeprazole- or rabeprazole-first’ strategy in GERD
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Gastroenterology"
DOI: 10.1007/s00535-019-01609-2
Abstract: Gastroesophageal reflux disease (GERD) can be treated using a vonoprazan-first strategy (first-line treatment with vonoprazan), or esomeprazole-first/rabeprazole-first strategies (first-line treatment with proton-pump inhibitors [PPIs], esomeprazole/rabeprazole, followed by a switch to vonoprazan). This cost-utility analysis used… read more here.
Keywords: strategy; rabeprazole first; first strategy; vonoprazan first ... See more keywords